典型文献
Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase Ⅱ trial
文献摘要：
ABSTRACTObjective: This study aimed to evaluate the safety, efficacy, and feasibility of the rituximab, fotemustine, pemetrexed, and dexamethasone (R-FPD) regimen followed by whole-brain radiotherapy (WBRT) for patients with primary central nervous system lymphoma (PCNSL). Methods: A prospective, single-center phase Ⅱ clinical trial was conducted. Patients with PCNSL newly diagnosed at the First Affiliated Hospital of Zhengzhou University between July 2018 and July 2020 were studied. The R-FPD regimen consisted of rituximab (375 mg/m2 i.v. on D0), fotemustine (100 mg/m2 i.v. on D1), pemetrexed (600 mg/m2 i.v. on D1), and dexamethasone (40 mg i.v. on D1-5). Patients 60 years or younger who showed a complete response (CR) were treated with 23.4 Gy of WBRT after the end of chemotherapy; those older than 60 years with CR were treated with a wait-and-see approach; and those who did not show CR after the 4th cycle of chemotherapy were given salvage WBRT 30 Gy + local tumor field irradiation up to 45 Gy, regardless of age. Results: A total of 30 patients were included. After 2 cycles, the objective response rate (ORR) was 96.5％ (28/29, 1 CR, 27 PR, 0 SD, and 1 PD). After 4 cycles, the ORR was 73.1％ (19/26, 11 CR, 8 PR, 4 SD, and 3 PD). After WBRT, the ORR was 90.9％ (10/11, 7 CR, 3 PR, and 1 SD). The grade Ⅲ and IV toxicity responses were mainly leukopenia (20.0％), thrombocytopenia (23.3％), and anemia (10.0％). Conclusions: Fotemustine-based therapy in combination with rituximab chemotherapy followed by WBRT can improve outcomes, providing ORR benefits and favorable tolerability in patients newly diagnosed with PCNSL.
文献关键词：
中图分类号：
作者姓名：
Jingjing Wu;Fenghua Gao;Wenhua Wang;Xudong Zhang;Meng Dong;Lei Zhang;Xin Li;Ling Li;Zhenchang Sun;Xinhua Wang;Xiaorui Fu;Linan Zhu;Mengjie Ding;Songtao Niu;Zhaoming Li;Yu Chang;Feifei Nan;Jiaqian Yan;Hui Yu;Xiaolong Wu;Zhiyuan Zhou;Jieming Zhang;Mingzhi Zhang
作者机构：
Cancer Research Institute,Department of Oncology,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,Henan,China
文献出处：
引用格式：
[1]Jingjing Wu;Fenghua Gao;Wenhua Wang;Xudong Zhang;Meng Dong;Lei Zhang;Xin Li;Ling Li;Zhenchang Sun;Xinhua Wang;Xiaorui Fu;Linan Zhu;Mengjie Ding;Songtao Niu;Zhaoming Li;Yu Chang;Feifei Nan;Jiaqian Yan;Hui Yu;Xiaolong Wu;Zhiyuan Zhou;Jieming Zhang;Mingzhi Zhang-.Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase Ⅱ trial)[J].癌症生物学与医学（英文版）,2022(07):1089-1099
A类：
Fotemustine,ABSTRACTObjective,fotemustine
B类：
combination,rituximab,first,line,induction,chemotherapy,followed,by,WBRT,newly,diagnosed,primary,central,nervous,system,lymphoma,prospective,phase,trial,This,study,aimed,evaluate,safety,efficacy,feasibility,pemetrexed,dexamethasone,FPD,regimen,whole,brain,radiotherapy,patients,PCNSL,Methods,single,center,clinical,was,conducted,Patients,First,Affiliated,Hospital,Zhengzhou,University,between,July,were,studied,consisted,D0,D1,years,younger,showed,complete,CR,treated,Gy,after,end,those,older,than,wait,see,approach,did,not,4th,given,salvage,local,tumor,field,irradiation,up,regardless,Results,total,included,After,cycles,objective,rate,ORR,PR,grade,IV,toxicity,responses,mainly,leukopenia,thrombocytopenia,anemia,Conclusions,can,improve,outcomes,providing,benefits,favorable,tolerability
AB值：
0.476336
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
